In a single‑center registry, baseline and 1‑year distances below 350 meters identified higher‑risk patients with transthyretin amyloid cardiomyopathy; changes in distance were prognostic mainly with stable therapy.
As ASE marks its 50th anniversary in Nashville, the meeting will showcase the latest echocardiography research, updated guidelines, the Kalmanson Lecture, and discussions on workforce challenges.